Novo Nordisk, the Danish pharmaceutical company behind the obesity treatment Wegovy and the diabetes therapy Ozempic, announced plans Wednesday to reduce its global workforce by approximately 9,000 positions, or about 11.5 percent of its 78,400 employees. Notifications to affected staff will begin immediately in accordance with local labor regulations. Of the total reductions, roughly 5,000 will occur in Denmark.
The restructuring is expected to generate annual savings of 8 billion Danish kroner, equivalent to around US $1.25 billion, by the end of 2026. In the current quarter, the company will record one-time costs of 9 billion kroner attributable to the restructuring, while forecasting savings of 1 billion kroner in the fourth quarter. In light of these financial adjustments, Novo Nordisk has revised its operating profit growth forecast for the year to range between 4 percent and 10 percent at constant exchange rates, down from its previous guidance of 10 percent to 16 percent.
The new chief executive, Mike Doustdar, who took over leadership in mid-2025, described the restructuring as a company-wide transformation aimed at simplifying operations, speeding decision-making, and reallocating resources toward its diabetes and obesity treatment areas. Investor reaction was muted, with U.S-listed shares of Novo Nordisk edging upward following the announcement, despite the company’s market value having fallen sharply by nearly 46 percent year-to-date as it contests increased competition and stalls in sales growth.
Workforce realignment impacts global corporate divisions
The move marks the largest reduction in Denmark’s corporate history. It comes as Novo Nordisk faces mounting pressure from rivals, including U.S. pharmaceutical firm Eli Lilly, and competition from compounded versions of GLP-1 weight-loss treatments. The company previously enacted a hiring freeze in August for positions deemed non-critical to operations.
Novo Nordisk said employees impacted by the job cuts will receive support in line with local requirements. The company did not offer further geographic details beyond the figures for Denmark regarding where the remaining reductions will occur. The restructuring follows a period of rapid workforce expansion during which Novo Nordisk nearly doubled its headcount amid soaring global demand for Wegovy and Ozempic.
The current step aligns staffing more closely with early-2024 levels. The company’s previous role as Europe’s most valuable listed company has shifted amid declining investor confidence tied to performance pressures and increasing market competition. By presenting concrete figures on staffing reductions, annual savings, one-off costs, and updated financial forecasts, Novo Nordisk provides a clear and transparent outline of its restructuring and short-term earnings path. – By Content Syndication Services.